Should healthy adults get a coronary calcium scan? Guidelines disagree

For most healthy adults, a coronary artery calcium (CAC) scan is not a routine screening test, and the US Preventive Services Task Force concluded in 2018 that the evidence is insufficient to recommend it for asymptomatic people in general [s2]. Cardiology guidelines are more specific rather than contradictory: they endorse the scan for one defined group — adults at intermediate cardiovascular risk for whom the decision to start a statin is genuinely uncertain, where the result can tip the choice either way [s1].

What the scan measures

A CAC scan is a fast, low-dose CT of the heart that quantifies calcified plaque in the coronary arteries, reported as an Agatston-unit score. Calcium in an artery wall is a durable footprint of atherosclerosis, so the score is a direct look at how much disease has already accumulated — as opposed to a risk calculator, which estimates the odds from age, blood pressure, cholesterol and the like. A score of zero means no detectable calcified plaque; a high score means a lot.

The evidence that the score predicts events

The prognostic value is well established. A 2018 analysis of the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort of 6,814 participants aged 45–84 and 51% women, followed them a median of 11.1 years, during which 500 (7.4%) had an atherosclerotic cardiovascular disease event [s3]. Risk rose steeply and steadily with the score: 10-year event rates among those with a CAC of zero ranged from 1.3% to 5.6% across age, sex and ethnic subgroups, while for those with a score above 300 they ranged from 13.1% to 25.6% [s3]. Everyone with a score above 100 was estimated to be above the 7.5% 10-year risk threshold regardless of subgroup, and each doubling of the calcium score corresponded to a 14% relative increase in risk, independent of standard risk factors [s3]. The "power of zero" is the part clinicians lean on most: a zero score put 10-year risk almost exclusively below 5% [s3].

Why the guidance bodies still differ

That predictive power is not the same as proof that scanning people improves their health, and this is where the two guidelines part company. The USPSTF reviewed CAC alongside the ankle-brachial index and high-sensitivity C-reactive protein, and found that adding them to existing risk models produced only small improvements in discrimination and risk reclassification, with the clinical meaning of those changes "largely unknown" [s2]. Crucially, it found inadequate evidence that treatment decisions guided by these tests actually reduce cardiovascular events or deaths — hence an "I statement," meaning insufficient evidence, not a recommendation against [s2]. It judged the harms of early detection and downstream intervention to be small, so the barrier to a stronger recommendation is missing benefit, not demonstrated harm [s2].

The 2019 American College of Cardiology/American Heart Association primary prevention guideline draws a narrower, more permissive line. It says that in adults at intermediate risk (a 10-year ASCVD risk of 7.5% to under 20%) or selected adults at borderline risk (5% to under 7.5%), if the statin decision remains uncertain, it is reasonable to measure a CAC score to guide the discussion — a Class IIa recommendation [s1]. It then attaches concrete thresholds: if the score is zero, it is reasonable to withhold statin therapy and reassess in five to ten years, as long as higher-risk conditions such as diabetes, a family history of premature coronary disease, or smoking are absent; a score of 1 to 99 favours starting a statin, especially at age 55 or older; and a score of 100 or higher, or at or above the 75th percentile for age and sex, supports starting one [s1].

What it means

The two positions are less a fight than a difference in question. The USPSTF is asking whether scanning the broad asymptomatic public has been shown to save lives, and the answer is that it has not been demonstrated [s2]. The cardiology guideline is asking a narrower clinical question — how to break a tie for a specific patient already weighing a statin — and for that use it endorses the scan [s1]. What neither supports is a CAC scan as a routine test for everyone, a healthy 30-year-old with no risk factors, or someone whose risk is already high enough that a statin is indicated regardless. The tradeoffs that make it a held decision — radiation, cost, and the incidental findings a chest CT can turn up — all argue for using it where a result would actually change what happens next. Because the score feeds directly into a medication decision, it belongs in a clinician-patient conversation, not a self-referred scan. This article is informational and not medical advice.

For related coverage, see how common silent plaque turns out to be in population imaging, what cholesterol numbers mean, and the debate over statin side effects.

Sources

• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease — Circulation, 2019-03-17
• Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: USPSTF Recommendation Statement — JAMA, 2018-07-11
• Ten-year association of coronary artery calcium with ASCVD events: the MESA study — European Heart Journal, 2018-04-23